Study guide

Arteritic optic neuropathy and GCA

European Board of Ophthalmology Diploma EBOD

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: EBOD Examination, Applications and Regulations

EBOD Format, Scoring and Revision Planning Eligibility, Applications and the Diploma Online Rules, Technical Preparation and Appeals

2 Chapter 2: Physical Optics, Photometry and Lenses

Light, refraction and total internal reflection Photometry, contrast, colour and adaptation Prisms, decentration and vector combination Vergence, astigmatic lenses and Sturm’s conoid

3 Chapter 3: Instrument Optics, Aberrations and Laser Physics

Cross-cylinder and diagnostic instrument optics Aberrations, duochrome and wavefront analysis Diffraction, polarization, lasers and OCT

4 Chapter 4: Refraction, Accommodation and Spectacle Prescribing

Objective and cycloplegic refraction Subjective refraction and binocular balance Accommodation, presbyopia and vertex distance Spectacle Materials, Measurement and Progressive Lenses

5 Chapter 5: Contact Lenses and Low-Vision Rehabilitation

Contact-lens optics, materials and tear lenses Contact-lens fit and complications Low-vision assessment and magnification Low-vision aids, calculations and ergonomics

6 Chapter 6: Extraocular Anatomy and Motor Physiology

Extraocular muscle anatomy and innervation Eye axes, kinematics and muscle actions Motor laws and orbital pulleys

7 Chapter 7: Binocular Vision and Amblyopia

Binocular vision, stereopsis and the horopter Suppression, correspondence and microtropia Sensory tests and amblyopia treatment

8 Chapter 8: Childhood Assessment and Strabismus Testing

Visual Development, Childhood Testing and Developmental Delay History, corneal reflexes and cover tests Motility patterns, three-step testing and Hess charts

9 Chapter 9: Esotropia, Exotropia and Vertical Deviations

Infantile and accommodative esotropia Exotropia classification and management Vertical Deviations, A–V Patterns and Skew

10 Chapter 10: Dysinnervation, Nystagmus and Muscle Surgery

Duane syndrome, Brown syndrome and restriction Nystagmus patterns and investigation Nystagmus and muscle surgery principles

11 Chapter 11: ROP and Paediatric Ocular Disease

Retinopathy of Prematurity: Screening, Classification and Follow-up Childhood Cataract, Leukocoria and Congenital Glaucoma Childhood Systemic Disease, Infection and Safeguarding

12 Chapter 12: Ocular Surface Anatomy and Infection

Corneal, Conjunctival and Scleral Structure: Examination and Sampling Bacterial keratitis, sampling and treatment Fungal, amoebic and herpetic keratitis Infectious, chlamydial and neonatal conjunctivitis

13 Chapter 13: Allergy, Cicatrisation and Surface Inflammation

Allergic eye disease, trachoma and phlyctenules Cicatrising Conjunctivitis: Mucous Membrane Pemphigoid and SJS/TEN Dry eye, blepharitis and meibomian dysfunction PUK, interstitial keratitis and scleritis

14 Chapter 14: Anterior Segment Dysgenesis and Corneal Dystrophies

Anterior Segment Dysgenesis, Aniridia and Congenital Corneal Opacity IC3D and epithelial or Bowman-layer dystrophies Stromal corneal dystrophies Endothelial corneal dystrophies

15 Chapter 15: Corneal Degeneration, Ectasia and Epithelial Failure

Corneal Degenerations, Pterygium, Band Keratopathy and Dellen Keratoconus and clinical ectasia signs Ectasia imaging, cross-linking and rehabilitation Recurrent Erosion, Neurotrophic Keratopathy and Vitamin A Deficiency

16 Chapter 16: Surface Reconstruction and Keratoplasty

Limbal Stem-Cell Failure, Tarsorrhaphy and Phototherapeutic Keratectomy PK, DALK and endothelial keratoplasty Corneal graft immunity and rejection recognition Graft rejection treatment and postoperative problems

17 Chapter 17: Lens Development, Cataract Assessment and Biometry

Lens Development, Congenital Shape and Ectopia Lentis Lens anatomy and age-related cataract phenotypes Cataract grading, secondary causes and childhood disease Optical and ultrasound biometry

18 Chapter 18: IOL Planning and Phacoemulsification

Keratometry and IOL power formulae Post-refractive biometry, toric alignment and IOL design Phaco fluidics and ultrasound delivery Wounds, OVDs and nucleus techniques

19 Chapter 19: Cataract Anaesthesia and Surgical Complications

Cataract Anaesthesia, Alternative Extraction and Combined Procedures IFIS, capsule rupture and compromised support Postoperative inflammation, haemorrhage and PCO

20 Chapter 20: Corneal and Intraocular Refractive Surgery

Excimer ablation, PRK and LASIK SMILE, surgical selection and complications Phakic IOLs and refractive lens exchange

21 Chapter 21: Presbyopia Procedures and Surface Therapeutics

Presbyopia Surgery, Monovision and Historical Refractive Procedures Surface antimicrobial and anti-inflammatory pharmacology Surface healing, amnion and cenegermin

22 Chapter 22: Aqueous Dynamics, Tonometry and Gonioscopy

Ciliary body and aqueous secretion Outflow and the Goldmann pressure model Tonometry, corneal thickness and biomechanics Gonioscopy optics, landmarks and indentation

23 Chapter 23: Angle, Disc and Visual-Field Assessment

Angle grading and anterior-segment imaging Optic-disc examination and documentation OCT and automated perimetry

24 Chapter 24: Glaucoma Progression, Suspects and Secondary Mechanisms

Field reliability and progression Ocular hypertension, suspects and juvenile glaucoma Lens-related glaucoma, aqueous misdirection and venous pressure

25 Chapter 25: POAG, Angle Closure and Pigmentary Disease

POAG, target pressure and normal-tension disease Angle-closure classification and mechanisms Acute angle closure, iridotomy and lens extraction Pseudoexfoliation and pigmentary glaucoma

26 Chapter 26: Glaucoma Medical, Laser and Surgical Treatment

Neovascular, uveitic and steroid-response glaucoma Glaucoma medicines, SLT and MIGS Trabeculectomy and drainage implants Nonpenetrating surgery, cyclodestruction and postoperative lasers

27 Chapter 27: Retinal Imaging, Diabetes and Vascular Occlusion

Retinal anatomy, examination and multimodal imaging Diabetic microangiopathy and NPDR classification PDR, macular oedema and diabetic trials Retinal vein and artery occlusions

28 Chapter 28: Uncommon Vascular Disease and Myopic Maculopathy

Macroaneurysm, sickle retinopathy and retinal periphlebitis Coats disease and leukocoria assessment MacTel and radiation retinopathy Myopic maculopathy and presumed ocular histoplasmosis

29 Chapter 29: Inherited Retina and Electrophysiology

Retinitis pigmentosa and inherited degeneration Stargardt, Best disease and retinal electrophysiology Cone disorders, stationary night blindness and syndromic retina

30 Chapter 30: AMD, Geographic Atrophy and Pachychoroid

AMD biology and clinical staging Drusen, geographic atrophy and neovascular phenotypes Neovascular AMD trials and treatment CSCR and the pachychoroid spectrum

31 Chapter 31: Retinal Breaks and Detachment Repair

PVD, peripheral degenerations and retinal breaks RRD localization and retinoschisis Detachment mechanisms, pneumatic retinopexy and scleral buckling

32 Chapter 32: Vitrectomy, Macular Surgery and Retinal Trauma

Vitrectomy and intraocular tamponades ERM, macular holes and PVR Retinal trauma, optic-disc pits and choroidal detachment

33 Chapter 33: Uveitis Classification and Non-Infectious Inflammation

SUN classification, grading and uveitis work-up Anterior and intermediate uveitis patterns HLA-B27, sarcoidosis, Behçet disease and VKH Posterior inflammatory patterns and immunomodulation

34 Chapter 34: Infectious Uveitis and Endophthalmitis

Toxoplasmosis and herpetic necrotizing retinitis Ocular syphilis and tuberculosis Immunosuppressed retinitis, toxocariasis and neuroretinitis Endophthalmitis diagnosis and treatment

35 Chapter 35: Optic Neuritis and Ischaemic Optic Neuropathy

Typical optic neuritis and ONTT NMOSD and MOGAD Arteritic optic neuropathy and GCA NAION and ischaemic neuropathy comparison

36 Chapter 36: Papilloedema, IIH and Afferent Localisation

Papilloedema recognition and Frisén grading IIH diagnosis and vision protection Disc drusen and pseudopapilloedema Afferent pathways and chiasmal localization

37 Chapter 37: Congenital, Inherited and Cortical Neuro-Ophthalmology

Cortical vision and higher visual syndromes Neuro-ophthalmic testing and congenital optic discs Inherited, compressive, infiltrative and nutritional optic neuropathies Transient visual loss, headache and neurological emergencies

38 Chapter 38: Central Motor Control and Cranial Nerve Palsies

Central ocular motor control and supranuclear disorders Third- and fourth-nerve palsies Sixth nerve, pontine gaze and cavernous sinus

39 Chapter 39: Myasthenia and Ocular Myopathy

Myasthenic ocular weakness Myasthenia testing and treatment Myopathy, CPEO and Kearns–Sayre syndrome

40 Chapter 40: Pupillary Pathways and Anisocoria

Pupillary pathways and afferent defects Horner syndrome and tonic pupil Light–near dissociation and pupil differentials

41 Chapter 41: Orbit, Thyroid Eye Disease and Ptosis Assessment

Orbital anatomy and thyroid eye disease Orbital infection and idiopathic inflammation Orbital masses, approaches and eye-removal procedures Lid anatomy and ptosis evaluation

42 Chapter 42: Lid Repair and Lacrimal Drainage

Ptosis repair, malposition and eyelid tumours Lash disorders, facial palsy and lid reconstruction Lacrimal drainage and epiphora testing Nasolacrimal obstruction, infection and DCR

43 Chapter 43: Lacrimal Gland Disease, Pathology and Intraocular Tumours

Lacrimal gland inflammation and tumours Ocular histology, specimen handling and special stains Immunophenotyping, molecular pathology and tumour genetics Uveal melanoma and retinoblastoma

44 Chapter 44: Lymphoma, Surface Tumours and Paraneoplastic Disease

Vitreoretinal lymphoma Surface tumours, uveal metastases and benign mimics Paraneoplastic retinopathy, treatment effects and counselling

45 Chapter 45: Ocular Trauma and Vascular Systemic Disease

Trauma terminology and prognostic scoring Chemical injury and surface preservation Open-globe emergency management Vascular, endocrine, pregnancy and renal eye disease

46 Chapter 46: Multisystem Disease and Ophthalmic Pharmacology

Immune, metabolic and multisystem ocular clues Phakomatoses and syndrome-specific surveillance Connective-tissue and metabolic ocular disease Drug delivery and systemic glaucoma effects

47 Chapter 47: Medication Toxicity, Professional Practice and Clinical Stations

Retinal and optic medication toxicity Prevention, consent and professional practice Directed clinical answers and station rehearsal

Arteritic optic neuropathy and GCA

Key Takeaways Explain This Topic AI

Visual-threat GCA requires immediate treatment while confirmatory investigation is arranged.

Current EULAR guidance supports temporal and axillary ultrasound first where expertise is available, with biopsy or other testing as indicated.

A negative biopsy can miss segmental disease and does not alone exclude GCA.

Last updated: October 2026

Vascular Anatomy of the Anterior Optic Nerve Head

Understanding the pathophysiology of ischaemic optic neuropathies requires precise knowledge of the microvascular supply to the optic nerve head (ONH). Unlike the superficial retinal nerve fibre layer (which receives perfusion from the central retinal artery), the deeper prelaminar, laminar, and retrolaminar regions of the optic disc are supplied exclusively by the posterior ciliary artery (PCA) circulation , derived from the ophthalmic artery:

Short Posterior Ciliary Arteries (SPCAs): Typically 2 to 3 main SPCAs pierce the posterior sclera medial and lateral to the optic nerve, branching into 10 to 20 terminal arterioles that coalesce within the scleral ring to form the anastomotic Circle of Zinn-Haller .

Watershed Zones: The SPCAs establish distinct sectoral vascular territories (superior vs. inferior, medial vs. lateral). The boundary between these terminal arteriolar territories forms a physiological "watershed zone" across the optic disc. This watershed arrangement explains why ischaemic insults to the ONH characteristically manifest as sectoral or altitudinal visual field defects respecting the horizontal meridian.

Anterior Ischaemic Optic Neuropathy (AION) denotes acute ischaemic infarction of the ONH supplied by the SPCAs. It is classified into two fundamentally distinct entities:

Arteritic AION (AAION): Infarction secondary to systemic vasculitic occlusion of the SPCAs, caused by Giant Cell Arteritis (GCA) .

Non-Arteritic AION (NAION): Infarction secondary to localized, non-vasculitic microvascular hypoperfusion of the SPCAs.

Arteritic Anterior Ischaemic Optic Neuropathy (AAION) & Giant Cell Arteritis

Giant Cell Arteritis (GCA), historically termed temporal arteritis or Horton disease, is a systemic, granulomatous necrotising vasculitis that selectively affects medium- and large-sized arteries possessing a well-developed internal elastic lamina. Its predilection for cranial branches of the external carotid artery (superficial temporal, facial, maxillary, occipital) and ophthalmic artery branches (SPCAs) renders it the single most devastating ophthalmic emergency in elderly patients.

Epidemiology & Pathogenesis

Age: Exclusively affects individuals aged ≥ 50 \ge 50 ≥ 50 years , with incidence rising exponentially with each decade (peak incidence 70 to 80 years, mean age ~75 years). GCA is virtually unknown below age 50.

Sex & Ethnicity: Female-to-male ratio of 2:1 to 3:1. Overwhelmingly common in populations of Northern European ancestry.

Immunopathogenesis: Activated dendritic cells in the arterial adventitia recruit CD4+ T-helper cells (Th1 and Th17 lineages) via chemokine signaling. Interferon-gamma (IFN- γ \gamma γ ) secreted by Th1 cells triggers macrophage recruitment, fusion into foreign-body or Langhans-type multinucleated giant cells , and the production of matrix metalloproteinases (MMPs) that degrade the internal elastic lamina . Concurrently, systemic overproduction of interleukin-6 (IL-6) drives the intense acute-phase systemic inflammatory response, while platelet-derived growth factor (PDGF) stimulates myofibroblast migration, producing concentric intimal hyperplasia and luminal thrombosis.

Ocular Manifestations of GCA

Arteritic AION (AAION, ~85% of ocular GCA): Sudden, profound, catastrophic, painless visual acuity loss in one eye. The vast majority present with visual acuity of count fingers, hand motions, or no light perception (NLP), accompanied by a striking relative afferent pupillary defect (RAPD).

Fundus Appearance: The characteristic ophthalmoscopic sign is chalky-white, pallid optic disc oedema ("pallid disc swelling"). Unlike the hyperaemic swelling of NAION, the severe transmural ischaemia of AAION starves prelaminar capillaries of blood, yielding an intensely pale, milky, swollen disc. Peripapillary flame haemorrhages and cotton-wool spots are common.

Cilioretinal Artery Occlusion: Because the cilioretinal artery (present in 20-30% of eyes) arises directly from the SPCA circulation rather than the central retinal artery, the combination of anterior ischaemic optic neuropathy and a cilioretinal artery occlusion is virtually characteristic of GCA.

Choroidal Hypoperfusion: Fluorescein angiography (FFA) reveals patchy, markedly delayed choroidal filling ( > 15 >15 > 15 seconds; normally < 5 <5 < 5 seconds), reflecting diffuse posterior ciliary artery occlusion.

Ocular Warning Signs: Amaurosis fugax (transient monocular visual obscurations occurring days or weeks prior to infarction) and transient binocular diplopia (due to ischaemic cranial nerve III or VI paresis or ischaemia of the extraocular muscles).

Systemic Features & High-Yield Diagnostic Signs

New-Onset Headache (60-80%): Severe, persistent, throbbing headache, typically temporal or occipital, frequently worse at night.

Scalp Tenderness: Pain elicited when brushing hair or resting the head on a pillow; palpation of the superficial temporal artery reveals a tender, nodular, thickened, pulseless, cord-like vessel.

Jaw Claudication (characteristic): Ischaemic cramping pain in the masseter and temporalis muscles elicited after 1 to 2 minutes of chewing or talking, resolving with rest. Jaw claudication carries the highest positive likelihood ratio ( LR+ 4.2 ) for a positive temporal artery biopsy.

Tongue Claudication & Infarction: Severe pain or ischaemic necrosis of the tongue due to lingual artery vasculitis.

Polymyalgia Rheumatica (PMR, 50%): Proximal, bilateral aching and morning stiffness in the neck, shoulder girdle, and hip girdle, lasting > 45 >45 > 45 minutes.

Constitutional Symptoms: Unexplained low-grade fever of unknown origin (FUO), profound fatigue, anorexia, and dramatic unintentional weight loss.

Diagnostic Evaluation and Urgent Treatment for GCA

Suspect GCA in an older patient with new headache, scalp tenderness, jaw claudication, constitutional symptoms, polymyalgia or ischaemic visual symptoms. Some patients lack systemic symptoms or have normal inflammatory markers. Pallid disc swelling and severe loss raise concern, but no isolated sign is sufficient.

Obtain ESR, CRP and blood count/platelets promptly without delaying treatment when suspicion is high. CRP units matter: 2.45 mg/dL equals 24.5 mg/L, not 10 mg/L. Do not apply an invented fixed triad sensitivity to rule disease out.

EULAR 2023 recommends ultrasound as first-line imaging when expertise and timely access are available, including temporal and axillary arteries. Alternative imaging or temporal-artery biopsy depends on availability, probability and concordance. Biopsy samples should be adequately long because of segmental skip lesions; an exact compulsory 1.5–2.5 cm interval is not shared by all guidance. A negative biopsy does not exclude disease when the clinical evidence is convincing.

Visual-threat GCA requires immediate high-dose systemic corticosteroids. IV methylprednisolone pulses are often used for acute ischaemic visual loss; if IV delivery would delay care, start appropriate oral treatment immediately. Investigations must not postpone protection of the other eye. Coordinate rheumatology for confirmation, taper and steroid-sparing treatment such as tocilizumab when indicated, with bone/metabolic/infection protection. Under IL-6 inhibition, normal CRP may not reliably indicate absence of relapse. Isolated PMR without GCA needs its own evaluation and treatment rather than automatically the same high-dose regimen.